Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2007Clinical Cancer Research

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

David B. Solit
David B. SolitAstraZeneca (United Kingdom)SIS. Percy IvyNational Institutes of HealthCKCatherine KopilMichael J. Fox Foundation

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Solit et al. (2007) studied this question.

synapsesocial.com/papers/69d80ec645af6083e6ae2c40https://doi.org/10.1158/1078-0432.ccr-06-1863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1GELDANAMYCIN, A NEW ANTIBIOTIC1970 · 469 citations
  2. 2Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models2005 · 164 citations
  3. 3Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function2002 · 629 citations
  4. 417-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models2004 · 89 citations
  5. 5Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors2005 · 244 citations